



Universiteit
Leiden
The Netherlands

Dose optimization of oral targeted therapies in oncology

Wit, D. de

Citation

Wit, D. de. (2015, October 6). *Dose optimization of oral targeted therapies in oncology*. Retrieved from <https://hdl.handle.net/1887/35807>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/35807>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/35807> holds various files of this Leiden University dissertation.

Author: Wit, Djoeke de

Title: Dose optimization of oral targeted therapies in oncology

Issue Date: 2015-10-06



Dose optimization of oral targeted therapies in oncology

Proefschrift

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof. mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties
te verdedigen op dinsdag 6 oktober 2015
klokke 15.00 uur

door

Djoeke de Wit
geboren te Alkmaar
in 1986

Promotiecommissie

Promotores Prof. Dr. H.-J. Guchelaar
 Prof. Dr. A.J. Gelderblom

Copromotor Dr. P.H. van Erp

Promotiecommissie Prof. Dr. P.H. van der Graaf (Universiteit Leiden)
 Prof. Dr. S. Sleijfer (Erasmus Universiteit Rotterdam)
 Prof. Dr. J.H. Beijnen (Universiteit Utrecht)

Voor Hanneke en René

Contents

Chapter 1	General introduction	10
Chapter 2	Individualized dosing of tyrosine kinase inhibitors – are we there yet? <i>Drug Discov Today</i> 2015;20(1):18-36	14
Chapter 3	A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using LC-MS/MS <i>J Chromatogr B Analyt Technol Biomed Life Sci.</i> 2013;937:33-43	52
Chapter 4	Dried blood spot analysis for therapeutic drug monitoring of pazopanib <i>J Clin Pharmacol.</i> 2015. Epub ahead of print.	72
Chapter 5	Therapeutic drug monitoring to individualize the dosing of pazopanib; a pharmacokinetic feasibility study <i>Ther Drug Monit.</i> 2015;37(3):331-338	88
Chapter 6	Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer. <i>Cancer Chemother Pharmacol.</i> 2014;73(1):87-96.	104
Chapter 7	Effect of gastrointestinal resection on sunitinib exposure in patients with GIST <i>BMC Cancer.</i> 2014;14:575-582	120
Chapter 8	Everolimus exposure-toxicity relationship and its population pharmacokinetics in patients with thyroid cancer <i>Submitted</i>	134
Chapter 9	General discussion and future perspective	152
	Summary/Samenvatting	164
	Curriculum vitae	172
	List of publications	174
	Dankwoord	176